+41 91 682 20 40 info@elixi-int.com

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/09/dda9809a6cb21a22caabcea6dbd46a96.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
SOLIRIS (eculizumab) – Alexion

SOLIRIS (eculizumab) – Alexion

Soliris is a pharma product indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.   Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease of the blood characterized by destruction of red blood cells by…

Read More

Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)

NEW HAVEN, Conn.--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced topline results from the REGAIN study, a Phase 3 registration trial of eculizumab (Soliris®) in patients with refractory generalized myasthenia gravis (gMG). Refractory gMG is an ultra-rare segment of MG—a debilitating,…

Read More